---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Executive summary: Disease burden"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Disease burden. Topics: Summary: definition and epidemiology; Summary: natural history, attack characteristics, and mortality; Summary: humanistic and economic burden; Summary: caregiver burden. 4 evidence topics quoted from 33 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary/disease-burden"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of Hereditary angioedema

<a id="topic-1.1.1-1"></a>

### Summary: definition and epidemiology

Hereditary angioedema (HAE) comprises a group of genetic disorders characterized by recurrent episodes of angioedema, typically mediated by bradykinin. It is most commonly caused by a deficiency of C1 inhibitor (C1-INH) and is subclassified into type 1 (quantitative deficiency) and type 2 (dysfunctional protein); a further form, HAE with normal C1-INH, occurs in patients with normal C1-INH function. HAE with C1-INH deficiency is autosomal dominant, about 5% of mutation carriers remain asymptomatic over their lifetime, and up to 25% of cases result from de novo mutations. In one cohort of 239 individuals, 90.4% had type 1 and 9.6% had type 2.

HAE is estimated to affect 1 in 50,000 people worldwide. One pooled analysis reported a diagnosed annual prevalence of 1.70 per 100,000 (95% confidence interval [CI], 1.58 to 1.83) for combined types, with pooled regional estimates of 1.43 per 100,000 in North America and 1.64 per 100,000 in Europe; a pooled analysis of 24 studies reported 1.22 cases per 100,000 (95% CI, 0.91 to 1.53). For all types of HAE in the United States, a claims-based algorithm yielded unadjusted prevalence estimates of 2.67, 2.61, and 2.43 per 100,000 for 2018, 2019, and 2020, corresponding to 9559, 9341, and 8694 people diagnosed with HAE; the corresponding estimates based on expert physician analysis were 2.13 (7602 people), 2.03 (7275), and 1.84 (6595). The sponsor's annual report states, citing HAE International as of October 2014, that HAE affected 1:30,000 to 1:80,000 individuals globally, or at least 7,000 patients in the US and at least 15,000 patients in the EU. The mean annual incidence of diagnosed HAE types 1 and 2 in Finland was 0.16 per 100,000, and a second analysis reported an incidence of 0.36 per 100,000 in 2024, measured as patients newly treated for HAE.

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/); [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/); [Craig et al. (2026b)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema); [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/); [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086); [Danielsson et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-2-2/current-use-of-hereditary-angioedema-hae-treatments-in-sweden-an-analysis-of-the-national-prescribed-drug-register)

<a id="topic-1.1.1-2"></a>

### Summary: natural history, attack characteristics, and mortality

Symptoms typically begin in childhood and worsen during puberty. In one cohort, symptoms began at a mean age of 11.2 years (SD 7.7), and only 370 (6.5%) of the following cumulative 5736 years were symptom-free. Untreated patients may experience attacks every 7 to 14 days on average; swelling worsens over the first 24 hours and subsides over the next 48 to 72 hours, usually lasting no more than 5 to 7 days. Abdominal involvement occurs in 70% to 90% of individuals, and laryngeal involvement, which accounts for less than 1% of all attacks, occurs at least once in about half of patients. Among 123 patients in another cohort, 61 (49.6%) experienced laryngeal edema, and the mean interval between onset and maximum development of laryngeal edema was 8.3 hours. At a Milan center, 227 patients reported 4244 attacks, of which 35% were not treated; median attack duration was 10 h with approved therapies and 45 h without treatment. A review of 65 articles reported mean or median delays from symptom onset to confirmed diagnosis of 3.9 to 26 years, and a guideline describes a decline in diagnostic delay from an average of 21 years in the 1970s to around 7 to 10 years currently.

In one cohort, 70 of 214 patients who had died asphyxiated during a laryngeal attack, 63 of them with undiagnosed HAE. Among 75 fatal events in another cohort, asphyxiation owing to laryngeal edema was the cause of death in 39 (52%); the diagnosis of HAE was made after death in 65 of the 75, the median time from symptom onset to death was 8 hours, and the life span of patients who died of laryngeal edema was reduced by 20 years compared with those who died of other causes. An analysis of studies including 3292 patients reported 411 deaths from asphyxia due to laryngeal edema, an average of one death for every 20 patients, and a guideline estimates the risk of death with laryngeal edema at 20% to 25% in the absence of a diagnosis. In another study, 36.9% of participants with HAE due to C1-INH deficiency and 15.4% of those with normal C1-INH reported family members who died from an HAE attack. Another cohort found no increased risk of death (odds ratio 0.69; 95% CI, 0.38 to 1.26) among HAE patients. The sponsor's annual report states a 30% risk of asphyxiation if an attack with airway obstruction remains untreated and, citing scientific publications, that patients experience a median of 14 attacks per year.

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/); [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Bork et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12767961/); [Zanichelli et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26304015/); [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z); [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/); [Minafra et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35526778/); [Minafra et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34687444/); [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/); [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-1.1.1-3"></a>

### Summary: humanistic and economic burden

In a survey of 457 respondents, SF-12 Physical and Mental Component Summary scores were lower than population norms (mean 43.7 versus 49.6 and 42.6 versus 49.4; p < 0.001 for each), 42.5% had depression scores above 8.5, “indicative of depressive symptomatology”, overall work impairment was 34%, and workers lost a mean of 3.3 days because of their most recent attack. In a survey of 260 participants, respondents reported a mean of 11.5 attacks (SD 14.2) in the past 6 months, 137 of 260 (52.7%) had an AE-QoL total score of 39 or higher, and 69 (26.5%) and 27 (10.4%) had moderate to severe anxiety and depression by HADS; a survey of 242 participants in Australia, Austria, Canada, France, Germany, Spain, Switzerland, and the United Kingdom reported moderate to severe anxiety and depression in 38.0% and 17.4%. Among 100 US adults receiving long-term prophylaxis and/or on-demand therapies, 80% reported at least 1 attack in the past year. The prevalence of presumptive post-traumatic stress disorder was between 20 and 25% among 77 participants with HAE due to C1-INH deficiency. In a US survey, the mean EQ-5D-5L index score in the treated cohort (94 respondents) was 0.849 “Today” and 0.568 “During the last treated attack”, and a European survey mapped to EQ-5D reported mean utilities of 0.44 during an attack and 0.72 between attacks.

In claims for 328 patients, mean annualized total HAE-related healthcare costs per patient were $165,348 before and $515,333 after starting long-term prophylaxis, driven by prophylaxis pharmacy costs (mean $395,845 per patient per year). Modeled on-demand-only treatment carried direct costs of $363,795 and indirect socioeconomic costs of $52,576 per patient per year, with medications accounting for 62.5% ($227,674). Another analysis reported annualized expenditures for on-demand prescriptions, hospitalizations, and emergency department visits averaging more than $200,000 even after initiation of subcutaneous prophylaxis. In 2006 and 2007, there were 5040 emergency department visits with HAE, of which 2059 (40.9%) resulted in a hospitalization, and mean HAE emergency department visit costs were $1479 (95% confidence interval, $1028 to 1929). In a cohort at a Milan center, the average cost per attack was €1183 (SD €789), or €11 912 per patient per year. A European patient survey estimated 20 days missed from work or school per year on average, and 51% of respondents indicated that HAE had hindered their career or educational advancement; a review reported an income loss of $3402 annually from work missed because of acute attacks.

Source: [Lumry et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20929608/); [Watt et al. (2026b)](https://link.springer.com/article/10.1186/s13023-025-04134-z); [Mendivil et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7893968/); [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/); [Christiansen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488251/); [O'Connor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12320545/); [Aygören-Pürsün et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5019462/); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/); [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/); [Zilberberg et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22195693/); [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/); [Aygören-Pürsün et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4105891/); [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="topic-1.1.1-4"></a>

### Summary: caregiver burden

In an international survey of 120 caregivers, sponsored by Takeda Development Center Americas, Inc., caregivers of pediatric patients reported being absent from work for a mean of 2.6 days (SD 5.8) in the preceding 4 weeks, while the children in their care missed a mean of 3.9 days (SD 6.2) of school; caregivers reported providing care for a mean of 23.5 days (SD 11.8) per month, 33.3% of caregivers of pediatric patients reported that caregiving limited their ability to work full time, and help provided by caregivers during the patient's most recent attack included administering HAE medication (51.5%). In a European patient survey, patients reported that their caregivers missed 3.3, 3.6, and 10.1 days among patients with attacks less than once a month, at least once a month but less than once a week, and at least once a week, respectively (p = 0.088). In interviews in the US and UK, six patients (43%) using icatibant required a parent or caregiver to administer it, including two of the 10 adult patients (20%) and all adolescents (n = 2). In a time trade-off valuation by members of the general public in England, the caregiver health state was rated 0.762 (SD 0.303).

Source: [Watt et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12895942/); [Aygören-Pürsün et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4105891/); [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/); [Lo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8864034/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
